Dr Crombie
Brem E et al. Odronextamab monotherapy in previously untreated patients with high-risk follicular lymphoma (FL): Results of the safety lead-in of the phase 3 Olympia-1 study. ASH 2024;Abstract 4411.
Budde LE et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study. Lancet Oncol 2022;23(8):1055-65. Abstract
Budde LE et al. Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: Pivotal results from a phase I/II study. ASH 2021;Abstract 127.
Falchi L et al. Fixed-duration epcoritamab + R2 drives deep and durable responses in patients with relapsed or refractory follicular lymphoma: 2-year follow-up from arm 2 of the Epcore NHL-2 trial. ASH 2024;Abstract 342.
Falchi L et al. Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the Mithic-FL1 trial. ASH 2024;Abstract 340.
Falchi L et al. Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns, and opportunities. Blood 2023;141(5):467-80. Abstract
Falchi L et al. EPCORE FL-1: Phase 3 trial of subcutaneous epcoritamab with rituximab and lenalidomide (R2) vs R2 alone in patients with relapsed or refractory follicular lymphoma. ASH 2023;Abstract 3053.
Ghosh N et al. SWOG 2308: Randomized phase III study of mosunetuzumab versus rituximab for low–tumor burden follicular lymphoma. JCO Oncol Adv 2025;2(1):e2500037. Abstract
Kim TM et al. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. Ann Oncol 2024;35(11):1039-47. Abstract
Linton KM et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): A phase 2 cohort of a single-arm, multicentre study. Lancet Haematol 2024;11(8):e593-605. Abstract
Linton KM et al. Epcoritamab SC monotherapy leads to deep and durable responses in patients with relapsed or refractory follicular lymphoma: First data disclosure from the Epcore NHL-1 follicular lymphoma dose-expansion cohort. ASH 2023;Abstract 1655.
Nastoupil L et al. CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma. EHA 2022;Abstract P1125.
Sehn LH et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood 2025;145(7):708-19. Abstract
Villasboas JC et al. Results of a second, prespecified analysis of the phase 2 study ELM-2 confirm high rates of durable complete response with odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) with extended follow-up. ASH 2023;Abstract 3041.
Vitolo U et al. Trial in progress: Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory follicular lymphoma and marginal zone lymphoma (OLYMPIA-5). EHA 2023;Abstract PB2266.
Dr Abramson
Ahmed S et al. Lisocabtagene maraleucel in R/R FL (TRANSCEND FL): Impact of prior lines of therapy, bendamustine exposure, and disease progression ≤ 24 months of initial systemic therapy. ICML 2025;Abstract 142.
Bartlett NL et al. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study. ASH 2022;Abstract 610.
Budde LE et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study. Lancet Oncol 2022;23(8):1055-65. Abstract
Dreyling M et al. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. Blood 2024;143(17):1713-25. Abstract
Dreyling M et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: Results from the randomized Triangle trial by the European MCL network. ASH 2022;Abstract.
Fowler NH et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial. Nat Med 2022;28(2):325-32. Abstract
Jacobson CA et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. Lancet Oncol 2022;23(1):91-103. Abstract
Linton KM et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): A phase 2 cohort of a single-arm, multicentre study. Lancet Haematol 2024;11(8):e593-605. Abstract
Morschhauser F et al. Lisocabtagene maraleucel in follicular lymphoma: The phase 2 TRANSCEND FL study. Nat Med 2024;30(8):2199-207. Abstract
Nastoupil L et al. Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Transcend FL 2-year follow-up. ASH 2024;Abstract 4387.
Neelapu SS et al. 5-year follow-up analysis from ZUMA-5: A phase 2 trial of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory indolent non-Hodgkin lymphoma. ASH 2024;Abstract 864.
Neelapu SS et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood 2024;143(6):496-506. Abstract
Neelapu SS et al. Long-term follow-up analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). ASH 2021;Abstract 93.
Shadman M et al. Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal phase II study. ASH 2024;Abstract 4407.
Taszner M et al. Primary analysis of the phase 2 ELM-2 study: Odronextamab in patients with relapsed/refractory follicular lymphoma. EHA 2024;Abstract S232.
Thieblemont C et al. Clinical outcomes of patients with high-risk relapsed/refractory follicular lymphoma treated with tisagenlecleucel: Phase 2 ELARA 4-year update. ASH 2024;Abstract 3034.
Thieblemont C et al. Three-factor prediction model for grade 2+ cytokine release syndrome in large B-cell lymphoma patients receiving epcoritamab monotherapy. ASH 2024;Abstract 4491.
Dr Sehn
Alderuccio JP et al. Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: A single-centre, single-arm, phase 2 trial. Lancet Haematol 2025;12(1):e23-34. Abstract
Alderuccio JP et al. Loncastuximab tesirine with rituximab induces robust and durable complete metabolic responses in high-risk relapsed/refractory follicular lymphoma. ASH 2024;Abstract 337.
Chavez JC et al. A randomized phase II study of mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). ASH 2024;Abstract 989.
Chavez JC et al. 3-year analysis of ZUMA-12: A phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL). ASH 2023;Abstract 894.
Cheson BD et al. Diffuse large B-cell lymphoma: New targets and novel therapies. Blood Cancer J 2021;11(4):68. Abstract
Cordoba R et al. Golcadomide (GOLCA), a cereblon E3 ligase modulator (CELMOD™) agent ± rituximab (R), in patients (PTS) with relapsed/refractory follicular lymphoma (R/R FL): Updated phase 1/2 study results. EHA 2025;Abstract PS1879.
Gopal AK et al. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study. J Clin Oncol 2018;36(23):2405-12. Abstract
Jurczak W et al. Nemtabrutinib, a noncovalent reversible BTK inhibitor in relapsed or refractory follicular lymphoma: Results from the phase 2 Bellwave-003 study. ASH 2024;Abstract 1634.
Østenstad B et al. SAKK 35/14 randomized trial of rituximab with or without ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. Hematol Oncol 2023;41(S2):117-9. Abstract
Reinke S et al. CD19 expression is retained in patients with relapsed/refractory follicular or marginal zone lymphoma after receiving tafasitamab, lenalidomide, and rituximab in the inMIND study. EHA 2025;Abstract PF1006.
Sehn LH et al. Post hoc analysis of outcomes by POD24 status from the inMIND study of tafasitamab plus lenalidomide and rituximab in relapsed or refractory follicular lymphoma. ICML 2025;Abstract 234.
Sehn LH et al. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Results from a phase 3 study (inMIND). ASH 2024;Abstract LBA-1.
Sehn L et al. MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 versus lenalidomide plus rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma. Hematol Oncol 2023;41(S2):168-70. Abstract
Trotman J et al. Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study. EHA 2023;Abstract P1080.
Zinzani PL et al. ROSEWOOD: A phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J Clin Oncol 2023;41(33):5107-17. Abstract